Genentech vs. Biogen: Jury Deliberates $122 Million Royalty Dispute in California Trial

In a legal battle that underscores the complexities of intellectual property rights in the biotechnology sector, Genentech Inc. has concluded a California federal trial against Biogen MA Inc., focusing on allegations of unpaid royalties amounting to $122 million. Genentech claims that Biogen has withheld these royalties for the supply of its multiple sclerosis drug. The matter now rests in the hands of a jury, which will decide whether Biogen should have continued to pay royalties beyond December 2018, when the main patent associated with the drug expired. In a strategic move, Genentech presented Biogen’s own financial projections to the jury, indicating royalty payments should continue past the patent expiration. For further details, the outlined issues can be explored through Law360.